Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04282668 · ClinicalTrials.gov registry record · Phase 1
A Study of TAS1440 With ATRA in Subjects With r/r AML
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT04282668 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 52 participants.
The verdict
NCT04282668, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a multicenter, 2-part, Phase 1 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of TAS1440 administered as a single agent and in combination with all-trans retinoic acid (ATRA) in participants with acute myeloid leukemia (AML) who have relapsed or are refractory (r/r) to prior treatment. The study duration is expected to be approximately 30 months.
Interventions
- DRUG TAS1440
- DRUG TAS1440 + ATRA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-03-15 |
| Est. Completion | 2024-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04282668
The ClinicalTrials.gov registry entry for NCT04282668 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAS1440 is the first listed.
NCT04282668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04282668 about?
NCT04282668 is a clinical study titled "A Study of TAS1440 With ATRA in Subjects With r/r AML". This is a multicenter, 2-part, Phase 1 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of TAS1440 administered as a single agent and in combination with all-trans retinoic acid (ATRA) in participants with acute myeloid leukemia (AML) who have relapse...
What is the current status of trial NCT04282668?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2020-03-15. Estimated completion is 2024-02-12.
What interventions are being tested in trial NCT04282668?
The interventions under investigation include: TAS1440 (DRUG), TAS1440 + ATRA (DRUG).
Who is sponsoring clinical trial NCT04282668?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.